Patent ID: 8414897

Claim:
A method of inhibiting the generation of a Th-17 effector cell in vivo, said method comprising the step of: exposing a Th-17 effector cell precursor cell to an antagonist of Th-17 function that inhibits Th-17 effector cell commitment, development, maintenance, survival, activity or a combination of the foregoing, wherein the antagonist is an antibody directed against TGF-β, IL-6, IL-17, or IL-23, an antibody directed against a receptor for TGF-β, IL-6, IL-17, or IL-23, a soluble form of a receptor for TGF-β, IL-6, IL-17, or IL-23, or the antagonist is IFN-γ, IFN-α, IFN-β, IL-4, IL-12 or a combination of the foregoing.